Telesis Bio (Telesis Bio) Retained Earnings : $-161.47 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Telesis Bio's retained earnings for the quarter that ended in Dec. 2023 was $-161.47 Mil.

Telesis Bio's quarterly retained earnings declined from Jun. 2023 ($-133.15 Mil) to Sep. 2023 ($-143.78 Mil) and declined from Sep. 2023 ($-143.78 Mil) to Dec. 2023 ($-161.47 Mil).

Telesis Bio's annual retained earnings declined from Dec. 2021 ($-65.27 Mil) to Dec. 2022 ($-113.74 Mil) and declined from Dec. 2022 ($-113.74 Mil) to Dec. 2023 ($-161.47 Mil).

Telesis Bio Retained Earnings Historical Data

The historical data trend for Telesis Bio's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio Retained Earnings Chart

Telesis Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

-8.30

-26.31

-65.27

-113.74

-161.47

Telesis Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial												-113.74	-124.86	-133.15	-143.78	-161.47

Telesis Bio Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Telesis Bio (NAS:TBIO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Telesis Bio (Telesis Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121

Website

https://www.telesisbio.com

Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.

Executives

Gregory J. Herrema	director	355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers	10 percent owner	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc	10 percent owner	1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p.	10 percent owner	1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc	10 percent owner	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider	director, 10 percent owner	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister	director, 10 percent owner	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler	officer: Chief Legal Officer	C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson	officer: Chief Technology Officer	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson	director, 10 percent owner, officer: President & CEO	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser	officer: Chief Operating Officer	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814